$1.78
4.71% day before yesterday
Nasdaq, Nov 07, 10:14 pm CET
ISIN
US47010C3007
Symbol
JAGX

Jaguar Health, Inc. Stock price

$1.78
-0.35 16.43% 1M
-9.22 83.82% 6M
-23.47 92.95% YTD
-22.97 92.81% 1Y
-15,016.97 99.99% 3Y
-66,451.97 100.00% 5Y
-963,899,998.22 100.00% 10Y
-2,402,662,498.22 100.00% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
+0.08 4.71%
ISIN
US47010C3007
Symbol
JAGX
Industry

Key metrics

Basic
Market capitalization
$6.6m
Enterprise Value
$33.7m
Net debt
$27.1m
Cash
$2.2m
Shares outstanding
1.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.6 | 0.5
EV/Sales
2.9 | 2.4
EV/FCF
negative
P/B
0.8
Financial Health
Equity Ratio
18.3%
Return on Equity
-394.0%
ROCE
-172.4%
ROIC
-
Debt/Equity
3.7
Financials (TTM | estimate)
Revenue
$11.8m | $14.3m
EBITDA
$-30.9m | $-23.7m
EBIT
$-32.8m | $-28.5m
Net Income
$-40.7m | $-37.2m
Free Cash Flow
$-27.7m
Growth (TTM | estimate)
Revenue
15.9% | 22.4%
EBITDA
-5.1% | 18.2%
EBIT
-4.7% | 7.5%
Net Income
-14.0% | 3.5%
Free Cash Flow
6.1%
Margin (TTM | estimate)
Gross
81.9%
EBITDA
-262.0% | -
EBIT
-278.1%
Net
-344.2% | -259.7%
Free Cash Flow
-234.3%
More
EPS
$-40.1
FCF per Share
$-18.1
Short interest
1.7%
Employees
49
Rev per Employee
$240.0k
Show more

Is Jaguar Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Jaguar Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Jaguar Health, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Jaguar Health, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Jaguar Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
12 12
16% 16%
100%
- Direct Costs 2.14 2.14
4% 4%
18%
9.67 9.67
19% 19%
82%
- Selling and Administrative Expenses 27 27
23% 23%
228%
- Research and Development Expense 16 16
11% 11%
132%
-31 -31
5% 5%
-262%
- Depreciation and Amortization 1.91 1.91
2% 2%
16%
EBIT (Operating Income) EBIT -33 -33
5% 5%
-278%
Net Profit -41 -41
14% 14%
-344%

In millions USD.

Don't miss a Thing! We will send you all news about Jaguar Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jaguar Health, Inc. Stock News

Neutral
Accesswire
3 days ago
Results of ongoing investigator-initiated proof-of-concept trial of crofelemer in United Arab Emirates (UAE) demonstrate disease progression modification and reduction of total parenteral support (PS) in pediatric intestinal failure patients ranging between 12% to 37% SAN FRANCISCO, CA / ACCESS Newswire / November 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmace...
Neutral
Accesswire
16 days ago
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / October 24, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective October 20, 2025, the Company granted 600 restricted stock units (RSUs) to New Employee 1, 600 RSUs to New Employee 2, and 300 RSUs to New Employee 3. The RSUs for New Employees 1, 2 and 3 vest over one year starting from each employee's ...
Neutral
Accesswire
about one month ago
Additional update: Results of ongoing investigator-initiated proof-of-concept trial in United Arab Emirates (UAE) demonstrate further reduction of total parenteral support (PS) (comprised of total parenteral nutrition and supplementary IV fluids) of approximately 37% SAN FRANCISCO, CA / ACCESS Newswire / October 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceut...
More Jaguar Health, Inc. News

Company Profile

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Head office United States
CEO Lisa Conte
Employees 49
Founded 2013
Website jaguar.health

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today